Editorial Disclosure: GLP-1 Editorial is an editorial publication operated by Ranika Editorial Group LLC. We do not provide medical care, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Our rankings are based on our published v3.0 transparency rubric, publicly available provider information, cited sources, and periodic review updates. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page and at /affiliate-disclosure.html.
Last reviewed: May 31, 2026
Next scheduled review: June 30, 2026
Reviewed by: Dr. Sam Saberian, Lead Medical Researcher
Edited by: Julliana Edwards, Editor
Methodology: GLP-1 Editorial v3.0 rubric
Categories · Multi-Specialty Directory · Updated 2026-05-11

Peptide & Therapy Categories

Browse U.S. telehealth providers and peptide therapeutics across six therapeutic categories. Every provider is scored on the v3.0 six-pillar transparency rubric, applied uniformly.

SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-11

Therapeutic categories

W
Weight Loss
GLP-1 receptor agonists for chronic weight management
6 peptides · 6 top providers reviewed
View category →
R
Recovery
Tissue repair, injury recovery, and inflammation control
7 peptides · 5 top providers reviewed
View category →
L
Longevity
Cellular aging, telomere maintenance, mitochondrial function
6 peptides · 5 top providers reviewed
View category →
C
Cognitive Enhancement
Memory, focus, neurogenesis, neuroprotection
6 peptides · 5 top providers reviewed
View category →
G
Growth Hormone
GH secretagogues, IGF-1 modulation, lean mass support
9 peptides · 5 top providers reviewed
View category →
S
Sexual Health
Libido, arousal, hormone modulation
5 peptides · 5 top providers reviewed
View category →

Why category matters

Telehealth providers are not interchangeable across therapeutic categories. A GLP-1-focused provider like NexLife has very different operational requirements (503A/503B pharmacy traceability, MD/DO oversight on titration, cardiovascular safety review) than a longevity provider that dispenses NAD+ or epithalon (research-grade peptides, lab integration for biomarkers). Match the provider to the use case.

Editorial team

Category reviews authored by Dr. Sam Saberian, medically reviewed by Alen A. Schwartz, MD, edited by Julliana Edwards. About our team →

Important medical and regulatory disclosure: Compounded semaglutide and compounded tirzepatide are not FDA-approved. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Editorial does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.